Bimodal administration of entacapone in Parkinson's disease patients improves motor control

L. Bet, S. R. Bareggi, F. Pacei, G. Bondiolotti, G. Meola, A. H V Schapira

Research output: Contribution to journalArticlepeer-review

Abstract

Catechol-O-methyl transferase (COMT) inhibition by entacapone enhances levodopa absorption and reduces 'off' time in Parkinson's disease (PD). We hypothesized that the administration of entacapone in a bimodal fashion (two doses 1 h apart) would enhance levodopa absorption and improve the motor symptoms of PD. Patients with PD (n = 17) were given immediate (IR)- or controlled (CR)-release levodopa each with either one or two doses of entacapone. Bimodal entacapone produced a significant increase in IR and CR levodopa half-life, 'area under the curve' (AUC), and Cmax with levodopa CR. For both IR and CR levodopa, bimodal entacapone resulted in a significant improvement in the Unified Parkinson's Disease Rating Scale part III (motor). Bimodal entacapone increased COMT inhibition, improved the pharmacokinetics of levodopa and improved motor scores for 6 to 8 h. Bimodal use of entacapone may be useful in selected patients to improve motor control and implies that controlled release COMT inhibition would be beneficial in PD patients.

Original languageEnglish
Pages (from-to)268-273
Number of pages6
JournalEuropean Journal of Neurology
Volume15
Issue number3
DOIs
Publication statusPublished - Mar 2008

Keywords

  • Catechol-O-methyl transferase
  • Continuous stimulation
  • Entacapone
  • Fluctuations
  • Levodopa
  • Parkinson's disease
  • Wearing off

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'Bimodal administration of entacapone in Parkinson's disease patients improves motor control'. Together they form a unique fingerprint.

Cite this